Literature DB >> 19240742

Deep hypothermia markedly activates the small ubiquitin-like modifier conjugation pathway; implications for the fate of cells exposed to transient deep hypothermic cardiopulmonary bypass.

Wei Yang1, Qing Ma, G Burkhard Mackensen, Wulf Paschen.   

Abstract

Various cardiovascular operations are performed during conditions of deep hypothermic circulatory arrest. Here we investigated the effects of deep hypothermia on the small ubiquitin-like modifier (SUMO) conjugation pathway using a clinically relevant animal model of deep hypothermic cardiopulmonary bypass (DHCPB). Deep hypothermic cardiopulmonary bypass induced a marked activation of the SUMO conjugation pathway and triggered a nuclear translocation of SUMO2/3-conjugated proteins. Furthermore, DHCBP significantly modified gene expression. Activation of the SUMO conjugation pathway is believed to protect neurons from damage caused by low blood flow. This pathway may, therefore, play a key role in defining the outcome of cells exposed to DHCPB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19240742     DOI: 10.1038/jcbfm.2009.16

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  22 in total

1.  Selective antegrade cerebral perfusion reduces brain injury following deep hypothermic circulatory arrest in the piglets' model by decreasing the levels of protein SUMO2/3-ylation.

Authors:  Bin Li; Yaobin Zhu; Aijun Liu; Wei Lu; Junwu Su; Jing Zhang; Zhiqiang Li; Xiangming Fan; Yinglong Liu
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 2.  SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases.

Authors:  Wei Yang; Wulf Paschen
Journal:  Proteomics       Date:  2014-10-28       Impact factor: 3.984

3.  Global SUMOylation facilitates the multimodal neuroprotection afforded by quercetin against the deleterious effects of oxygen/glucose deprivation and the restoration of oxygen/glucose.

Authors:  Yang-Ja Lee; Joshua D Bernstock; Nandakumar Nagaraja; Brian Ko; John M Hallenbeck
Journal:  J Neurochem       Date:  2016-06-06       Impact factor: 5.372

4.  Results of proximal arch replacement using deep hypothermia for circulatory arrest: is moderate hypothermia really justifiable?

Authors:  Brian Lima; Judson B Williams; S Dave Bhattacharya; Asad A Shah; Nicholas Andersen; Jeffrey G Gaca; G Chad Hughes
Journal:  Am Surg       Date:  2011-11       Impact factor: 0.688

5.  Moderate hypothermia induces marked increase in levels and nuclear accumulation of SUMO2/3-conjugated proteins in neurons.

Authors:  Liangli Wang; Qing Ma; Wei Yang; G Burkhard Mackensen; Wulf Paschen
Journal:  J Neurochem       Date:  2012-09-12       Impact factor: 5.372

6.  Analysis of oxygen/glucose-deprivation-induced changes in SUMO3 conjugation using SILAC-based quantitative proteomics.

Authors:  Wei Yang; J Will Thompson; Zhengfeng Wang; Liangli Wang; Huaxin Sheng; Matthew W Foster; M Arthur Moseley; Wulf Paschen
Journal:  J Proteome Res       Date:  2011-12-01       Impact factor: 4.466

7.  Neuron-specific SUMO knockdown suppresses global gene expression response and worsens functional outcome after transient forebrain ischemia in mice.

Authors:  Lin Zhang; Xiaozhi Liu; Huaxin Sheng; Shuai Liu; Ying Li; Julia Q Zhao; David S Warner; Wulf Paschen; Wei Yang
Journal:  Neuroscience       Date:  2016-12-03       Impact factor: 3.590

8.  Development of a high-throughput screening assay for inhibitors of small ubiquitin-like modifier proteases.

Authors:  Wei Yang; Liangli Wang; Wulf Paschen
Journal:  J Biomol Screen       Date:  2013-03-07

Review 9.  SUMO and ischemic tolerance.

Authors:  Yang-ja Lee; John M Hallenbeck
Journal:  Neuromolecular Med       Date:  2013-06-18       Impact factor: 3.843

10.  DJ-1 ameliorates ischemic cell death in vitro possibly via mitochondrial pathway.

Authors:  Yuji Kaneko; Hideki Shojo; Jack Burns; Meaghan Staples; Naoki Tajiri; Cesar V Borlongan
Journal:  Neurobiol Dis       Date:  2013-09-21       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.